Biocorp combines its smart sensor, Mallya, for insulin pen injectors, with Diabeloop’s automated insulin delivery systems. This specialist in the development and manufacture of connected medical solutions and devices, located in Issoire (Puy-de-Dôme), formalized its partnership with this start-up from Isère on March 19, 2021. “We are very happy to unite our R&D capabilities with the common ambition to improve the quality of care for diabetic patients. The technological platform developed by Diabeloop in the field of insulin pumps, which reproduces the functioning of the pancreas thanks to AI, has real potential in the insulin pen market ”, explains Éric Dessertenne, CEO of Biocorp.
–
Through this partnership, Biocorp and Diabeloop want to establish themselves in a market with great potential, estimated at more than $ 9 billion by 2022. According to the explanations of Marc Julien, co-manager at Diabeloop, “this collaboration opens up new possibilities to bring Diabeloop’s interoperable technology to people who live with diabetes and use the pens to perform their multiple insulin injections each day ”.
–
